abemaciclib

Also known as CS-1230, HY-16297A, LY 2835219, LY2835219

Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.

Key facts

Drug.image: Abemaciclib.svg
Drug.image_class: skin-invert-image
Drug.tradename: Verzenio, Verzenios, Ramiven, others
Drug.DailyMedID: Abemaciclib
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: L01
Drug.ATC_suffix: EF03
Drug.legal_AU: S4
Drug.legal_CA: Rx-only
Drug.legal_CA_comment: / Schedule D
Drug.legal_US: Rx-only
Drug.legal_EU: Rx-only
Drug.bioavailability: 45%
Drug.protein_bound: 96.3%
Drug.elimination_half life: 18.3 hrs
Drug.excretion: 81% via feces, 3% via urine
Drug.CAS_number: 1231929-97-7
Drug.PubChem: 46220502

via Wikipedia infobox

Wikidata facts

Mass: 506.272

Show 3 more facts

Commons category: Abemaciclib
chemical formula: C₂₇H₃₂F₂N₈
canonical SMILES: CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F

Sources (4)

via Wikidata · CC0

~5 min read